Mesoblast MESO 深 沪
交易中 10-16 11:25:29 美东时间
13.57
-0.380
-2.72%
华盛通- 最 高13.91
- 今 开13.91
- 成交量 8.44万股
- 最 低 13.532
- 昨 收 13.95
- 总市值 17.65亿
- 52周最高 21.50
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 13.05
- 委 比 -69.25%
- 总股本 1.30亿
- 历史最高 58.4744
- 量 比 1.50
- 振 幅 2.71%
- 历史最低 1.9406
- 每 手 1
- 风险率 1.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mesoblast Updates ASX on October 14 Capital Structure Changes
Mesoblast ( ($MESO) ) just unveiled an update. On October 14, 2026, Mesoblast L...
10-15 19:57
Mesoblast Sets Details for 2026 Annual General Meeting
The latest announcement is out from Mesoblast Limited ( ($AU:MSB) ). Mesoblast ...
10-12 13:27
Mesoblast Files Updated Corporate Governance Statement and ASX Appendix 4G
Mesoblast Limited ( ($AU:MSB) ) just unveiled an update. Mesoblast Limited has ...
10-12 13:17
Mesoblast Limited (MEOBF) Receives a Buy from Bell Potter
Bell Potter analyst John Hester maintained a Buy rating on Mesoblast Limited to...
10-09 06:35
Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches
An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblas...
09-24 08:30
美股大行评级 | 潜在涨幅1024.26%！Ascendiant Capital上调PAVmed目标价至57美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从56美元升至57美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9.25美元升至9.5美元
08-28 16:15
Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39
Piper Sandler analyst Edward Tenthoff reiterates Mesoblast (NASDAQ:MESO) with a Overweight and raises the price target from $35 to $39.
08-28 01:25
Mesoblast shares are trading higher after the company reported better-than-expected FY sales results.
Mesoblast shares are trading higher after the company reported better-than-expected FY sales results.
08-27 22:34
